Health Trials

Hypofractionated Radiotherapy

4

Review clinical trials related to Hypofractionated Radiotherapy. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma

The purpose of this study is to investigate the safety and efficacy of HFRT plus neoadjuvant ICT in locally advanced resectable GEJA.

Participants needed: 84
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: West China HospitalUpdated: Jan 6, 2026Locations: 4
Eligibility criteria

Histologically and/or cytologically confirmed diagnosis of locally advanced aden... [+6]

Confirmed dMMR or MSI-H by immunohistochemistry or genetic testing. [+9]

Read more
Status: Recruiting

Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma

The purpose of this study is to investigate the safety and efficacy of conversion therapy using HFRT combined with ICT in locally advanced or metastatic unresectable GEJA.

Participants needed: 88
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: West China HospitalUpdated: Nov 28, 2025Locations: 4
Eligibility criteria

Histologically and/or cytologically confirmed diagnosis of locally advanced gast... [+29]

Diagnosed as mismatch repair deficient (dMMR) or microsatellite instability-high... [+46]

Read more
Status: Recruiting

Real World Study of Platinum Containing Dual Drug Chemotherapy Followed by Large Fractionated Radiotherapy Combined withTislelizumab in Stage IIIB/C-IV Non-small Cell Lung Cancer Patient

In clinical practice, some patients cannot tolerate concurrent chemoradiotherapy. The purpose of this study is to observe the efficacy and safety of platinum-based doublet chemotherapy followed by hypofractionated radiotherapy and Tislelizumab in patients with stage IIIB/C-IV non-squamous non-small cell lung cancer. This study aims to provide more treatment options for patients with locally advanced non-small cell lung cancer.

Participants needed: 20
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Zibo Municipal HospitalUpdated: Sep 30, 2025Locations: 1
Eligibility criteria

Age 18-75 years old, gender is not limited; [+3]

Patients with uncontrolled autoimmune diseases; [+6]

Read more
Status: Recruiting

Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Single-Arm, Phase II Study

In clinical practice, some patients cannot tolerate concurrent chemoradiotherapy. The purpose of this study is to observe the efficacy and safety of Tislelizumab combined with platinum-based doublet chemotherapy followed by hypofractionated radiotherapy and Tislelizumab in patients with stage IIIB/C-IV non-squamous non-small cell lung cancer. This study aims to provide more treatment options for patients with locally advanced non-small cell lung cancer.

Participants needed: 20
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Zibo Municipal HospitalUpdated: Jul 25, 2025Locations: 1
Eligibility criteria

Age 18-75 years old, gender is not limited; [+3]

Patients with uncontrolled autoimmune diseases; [+7]

Read more